(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 16 December 2004 (16.12.2004)

PCT

(10) International Publication Number WO 2004/108938 A3

(51) International Patent Classification7: C12N 15/861. C07K 7/06, A61K 48/00

(21) International Application Number:

PCT/GB2004/002421

(22) International Filing Date: 7 June 2004 (07.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 03 13132.3 6 June 2003 (06.06.2003)

(71) Applicant (for all designated States except US): ICH PRODUCTIONS LIMITED [GB/GB]; 30 Guilford Street, London WC1N 1EH (GB).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): HART, Stephen, Lewis [GB/GB]; Institute of Child Health, 30 Guilford Street, London WC1N 1EH (GB). WRITER, Michele [GB/GB]; Institute of Child Health, 30 Guilford Street, London WC1N 1EH (GB).
- (74) Agents: SILVESTON, Judith et al.; Abel & Imray, 20 Red Lion Street, London WC1R 4PQ (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 12 May 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PEPTIDE LIGANDS OF DENDRITIC CELLS FOR NUCLEIC ACID VECTOR TARGETING

(57) Abstract: A peptide consisting of or comprising an amino acid sequence selected from a) Px¹X²X³ T [SEQ.ID.NO.:1]; b) PSX4S [SEQ.ID.NO.:2]; C) QX5X6X7Q [SEQ.ID.NO.:3]; d) SX8S [SEQ-ID.NO.:4], in which X1, X2 and X3, which may be the same or different, each represents an amino acid residue; X² is preferably N or L; X⁴ represents an amino acid residue, preferably N or L; X5 and X7, which may be the same or different, each represents an amino acid residue, X6 represents an amino acid residue having an amide side chain; and X8 represent an amino acid having an aliphatic side chain, which peptide binds to dendritic cells and also to other types of cells. The peptide may be used a target non-viral and viral vectors to such cells.





Interd al Application No

PCT/GB2004/002421 A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N15/861 C07K7/06 A61K48/00 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N C07K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, CHEM ABS Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Χ IVANENKOV VASILY V ET AL: "Targeted 1-15. delivery of multivalent phage display 30-107 vectors into mammalian cells" BIOCHIMICA ET BIOPHYSICA ACTA, AMSTERDAM, vol. 1448, no. 3, 11 January 1999 (1999-01-11), pages 463-472, XPO02157575 ISSN: 0006-3002 abstract; page 463, right-hand column, Y. 1-15. lines 3-6; table 1, third peptide 30-107 WO 98/44121 A (MEHTALI MAJID ; LEGRAND VALERIE (FR); TRANSGENE SA (FR); BOULANGER X 1-15, 30-107 PIE) 8 October 1998 (1998-10-08) abstract; Seq. ID 1; paragraph joining pages 4 and 5; page 10, lines 14-17; claims 3,6-8,29,33-34 X Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents : "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the International "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to fillno date "L" document which may throw doubts on priority claim(s) or which is clied to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-"O" document referring to an oral disclosure, use, exhibition or other means ments, such combination being obvious to a person skilled in the art. "P" document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the International search report 0 1 03 05 4 November 2004 Name and mailing address of the iSA Authorized officer European Patent Office , P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2340, Tx. 31 651 epo nl,

Fausti, S

Fax: (+31-70) 340-3016

Intern: Application No
PCT/GB2©04/002421

Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
WO 02/057445 A (MURUGANANDAM ARUMUGAM; STANIMIROVIC DANICA (CA); NARANG SARAM (CA); N) 25 July 2002 (2002-07-25) abstract; table 1, Seq. IDs 61,82; claims 44-47	1-15, 30-107
WO 03/004646 A (O'MAHONY DANIEL J; BRAYDEN DAVID (IE); BYRNE DARAGH (IE)) 16 January 2003 (2003-01-16) abstract; table 4, the 29th peptide on page 50	1-15, 30-107
DE 198 45 251 A (UNIV EBERHARD KARLS) 9 March 2000 (2000-03-09) abstract; page 2, lines 21-29; Seq. IDs 1, 39 and 40 on pages 6-7	1-15, 30-107
BOER J ET AL: "Design and synthesis of potent and selective alpha(4)beta(7) integrin antagonists" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 44, 26 July 2001 (2001-07-26), pages 2586-2592, XP002214393 ISSN: 0022-2623	1-15, 30-34
abstract; page 2586, paragraph joining left- and right-hand columns; tables 1-2	1-15, 30-83, 97-107
WO 03/008537 A (CTL IMMUNOTHERAPIES CORP) 30 January 2003 (2003-01-30) abstract; Seq. IDs 393,394,398,399,537,538 of table 1C.	1-15, 30-34
WO 91/18010 A (INST MEDICAL W & E HALL; SWINBURNE LTD (AU); MACFARLANE BURNET CENTRE) 28 November 1991 (1991-11-28) abstract; table 2, 4th peptide	1-15, 30-34
WO 98/54347 A (HART STEPHEN LEWIS; INST OF CHILD HEALTH (GB)) 3 December 1998 (1998-12-03) cited in the application abstract; page 5, line 22 to page 10, line 15; claim 47	1-15, 30-83, 97-107
WO 02/072616 A (ICH PRODUCTIONS LTD; WRITER MICHELE (GB); HART STEPHEN LEWIS (GB)) 19 September 2002 (2002-09-19) abstract; page 5, lines 2-7; examples 1-2; claims 21-81	1-15, 30-107
	STANIMIROVIC DANICA (CA); NARANG SARAM (CA); N) 25 July 2002 (2002-07-25) abstract; table 1, Seq. IDs 61,82; claims 44-47 WO 03/004646 A (O'MAHONY DANIEL J; BRAYDEN DAVID (IE); BYRNE DARAGH (IE)) 16 January 2003 (2003-01-16) abstract; table 4, the 29th peptide on page 50 DE 198 45 251 A (UNIV EBERHARD KARLS) 9 March 2000 (2000-03-09) abstract; page 2, lines 21-29; Seq. IDs 1, 39 and 40 on pages 6-7 BOER J ET AL: "Design and synthesis of potent and selective alpha(4)beta(7) integrin antagonists" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 44, 26 July 2001 (2001-07-26), pages 2586-2592, XP002214393 ISSN: 0022-2623 abstract; page 2586, paragraph joining left- and right-hand columns; tables 1-2 WO 03/008537 A (CTL IMMUNOTHERAPIES CORP) 30 January 2003 (2003-01-30) abstract; Seq. IDs 393,394,398,399,537,538 of table 1C. WO 91/18010 A (INST MEDICAL W & E HALL; SWINBURNE LTD (AU); MACFARLANE BURNET CENTRE) 28 November 1991 (1991-11-28) abstract; table 2, 4th peptide WO 98/54347 A (HART STEPHEN LEWIS; INST OF CHILD HEALTH (GB)) 3 December 1998 (1998-12-03) cited in the application abstract; page 5, line 22 to page 10, line 15; claim 47 WO 02/072616 A (ICH PRODUCTIONS LTD; WRITER MICHELE (GB); HART STEPHEN LEWIS (GB)) 19 September 2002 (2002-09-19)

Intern: I Application No PC7/GB2004/002421

C.(Continu	PC1/GB2004/002421	
Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to daim No.
Α	WO 01/58940 A (GENVEC INC) 16 August 2001 (2001-08-16) abstract; example 1; page 5, first paragraph; page 6, second paragraph, paragraph joining pages 6 and 7	
A	PEREBOEV A V ET AL: "Coxsackievirus-adenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic cells." GENE THERAPY. SEP 2002, vol. 9, no. 17, September 2002 (2002-09), pages 1189-1193, XP002303755 ISSN: 0969-7128 abstract; figures 1 and 3	
	:10 (continuation of second sheet) (January 2004)	

In

onal application No. PCT/GB2004/002421

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 97, 99-101 and 108 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. In particular, the method of claim 108 is to be considered as such because it can be carried out "in vivo". 2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Corntinuation of item 3 of first sheet)
This International Searching Authority found multiple Inventions in this International application, as follows:
see additional sheet
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. X No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1 (partially), 2-15, 30-107 (partially)
i (partially), 2-15, 30-10/ (partially)
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1 (partially), 2-15, 30-107 (partially)

Peptides comprising the motif of Seq. ID 1 (i.e. PXXXT), compositions and medical uses thereof, as well as antibodies and methods for producing said compositions: transfection mixtures, complexes, vectors, kits,...

2. claims: 1 (partially), 16-20, 30-107 (partially)

Peptides comprising the motif of Seq. ID 2 (i.e. PSXS), compositions and medical uses thereof, as well as antibodies and methods for producing said compositions: transfection mixtures, complexes, vectors, kits,...

3. claims: 1 (partially), 21-25, 30-107 (partially)

Peptides comprising the motif of Seq. ID 3 (i.e. QXXXQ), compositions and medical uses thereof, as well as antibodies and methods for producing said compositions: transfection mixtures, complexes, vectors, kits,...

4. claims: 1 (partially), 26-29, 30-107 (partially)

Peptides comprising the motif of Seq. ID 4 (i.e. SXS), compositions and medical uses thereof, as well as antibodies and methods for producing said compositions: transfection mixtures, complexes, vectors, kits,...

5. claim: 108

Method for the identification of siRNAs.

ormation on patent family members

Interr Application No
PCI/GB2004/002421

			Database I			CI/UB	2004/002421
	ent document in search report		Publication date		Patent family member(s)		Publication date
WO	9844121	Α	08-10-1998	FR	2761688		09-10-1998
				FR	2761689		09-10-1998
	•			ΑU	741728	B2	06-12-2001
				AU	7054798		22-10-1998
		•		CA	2285565		08-10-1998
				EΡ	0991763	Δ1	12-04-2000
				WO	9844121	V.1	
			•	JP			08-10-1998
	•					T	13-11-2001
				US	6569677	RI	27-05-2003
		~		US	2003175243		18-09-2003
WO	02057445	Α	25-07-2002	ΑU	6885501		03-12-2001
				WO	0190190		29-11-2001
	•			WO	02057445	A1	25-07-2002
				CA	2380443	A1	29-11-2001
				CA	2441903		25-07-2002
				ĒΡ	1328626		23-07-2003
				นิร	2003190598		09-10-2003
				üS	2004161738		19-08-2004
	02004645		10 01 0000				
WU	03004646	Α	16-01-2003	CA	2443644		16-01-2003
				EP	1419252		19-05-2004
				WO	03004646		16-01-2003
				US	2003211476	A1	13-11-2003
				CA	2451741	A1	16-01-2003
				EP	1432729		30-06-2004
				WO	03004517		16-01-2003
				US	2003096354		22-05-2003
DE	19845251	Α΄	09-03-2000	DE	19845251	 Δ1	09-03-2000
		••	12 13 2000	MO	0014215		16-03-2000
				EP	1109897		27-06-2001
	02000507						
WÜ	03008537	Α	30-01-2003	CA	2442386		17-10-2002
				EP	1383528		28-01-2004
				MO	03008537		30-01-2003
			•	MO	02081646		17-10-2002
				US	2003220239		27-11-2003
				US	2003138808	A1	24-07-2003
WO	9118010	Α	28-11-1991	AU	7869191	A	10-12-1991
			· - -	WO	9118010		28-11-1991
MU 	9854347	Α	03-12-1998	AU	7667200	^	20 12 1000
110	JUJ7J7/	М	03-15-1330	CA	7667398 2288840		30-12-1998
							03-12-1998
				EP	1003898		31-05-2000
				WO	9854347		03-12-1998
				. Jb	2002502243	-	22-01-2002
				US	2003013644		16-01-2003
			,	US	2002042384	Al	. 11-04-2002
WO	02072616	Α	19-09-2002	CA	2470152	A1	19-09-2002
				EP	1368371		10-12-2003
				ΜO	02072616		19-09-2002
				JP	2004532197		21-10-2004
				US	2004132973		08-07-2004
	0158940	Α	16-08-2001	ΑU	3498101		20-08-2001

rmation on patent family members

Intern: al Application No
PC1/uB2004/002421

				PC1/6820	004/002421
Patent document cited in search report	Publication date		Patent family member(s)		Publication .date
WO 0158940 A		WO US	0158940 2001047081	A2 A1	16-08-2001 29-11-2001
					·